Psychiatric News (4/3) reported a study published in JAMA Psychiatry found that “among adults with methamphetamine use disorder, mirtazapine delivered in routine clinical practice reduced methamphetamine use compared with a placebo.” Researchers in 344-patient study found that “12 weeks of mirtazapine (30 mg/day) delivered in routine clinical practice produced a greater reduction in methamphetamine use days than placebo. There were no unexpected safety concerns from mirtazapine.”
Related Links:
— “Mirtazapine Effectively Treats Methamphetamine Use Disorder,Psychiatric News , April 3, 2026